The Monash Partners Comprehensive Cancer Consortium (MPCCC) is the Cancer and Blood Diseases Theme. MPCCC is a strategic alliance of health service and research organisations working in partnership to improve outcomes for people affected by cancer. Our partners work collaboratively to bring a coordinated, multidisciplinary approach to innovating clinical oncology practices, improving cancer services and delivering the next generation of research for better cancer prevention, early detection and treatment of cancer.
Our goal is to improve patient experience and outcomes across the cancer care continuum, through world-class research and quality improvement.
This ambition will be realised by linking our expertise across basic translational, clinical, health service, population health and epidemiological research with the service delivery expertise of our clinical partners.
You can find out more about Monash Partners Comprehensive Cancer Consortium work here or follow MPCCC on Twitter and LinkedIn .
We believe cancer research and service improvement are integrally linked and should be driven by the needs and priorities of the community. Our mission is to build a culture of collaboration and innovation that transcends organisational boundaries and drives improved cancer outcomes. MPCCC priorities are to:
- Design and deliver a holistic and equitable cancer research and improvement agenda
- Build capacity for innovations in cancer treatments by linking discovery, pre-clinical and clinical research
- Drive improvements in cancer care through the strategic use of data to inform priorities and measure outcomes
- Establish and maintain strategic collaborations that align cancer research and improvement activities with health and research policy agenda
- Use appropriate governance and processes to lead and promote a world-class cancer research and improvement agenda.
You can find out more about Monash Partners Comprehensive Cancer Consortium work here or follow MPCCC on Twitter and LinkedIn .
The Theme is led by the MPCCC Executive. Members include: Professor Melissa Southey, Professor Eva Segelov, Professor John Zalcberg OAM, Professor Roger Daly, Associate Professor Zee Wan Wong, Dr Andrew Haydon, Ms Anna Kilgour, and Ms Selena Sherwell.
Professor Melissa Southey
Read More
Professor Melissa Southey is Research Director, MPCCC; Chair of Precision Medicine, School of Clinical Sciences at Monash Health; and Director, Biobanking Victoria, Monash University.
Professor Eva Segelov
Read More
Professor Eva Segelov is Professor and Director of Oncology, Monash Health and Monash University .
Associate Professor Andrew Haydon
Read More
Associate Professor Andrew Haydon is joint Clinical Director, Southern Melbourne Integrated Cancer Service (SMICS); and Medical Oncologist, Alfred Health.
Associate Professor Zee Wan Wong
Read More
Associate Professor Zee Wan Wong is joint Clinical Director, Southern Melbourne Integrated Cancer Service (SMICS); Head of Oncology, Peninsula Health; Adjunct Clinical Associate Professor, Monash University; and Senior Lecturer, University of Melbourne Medical School, Department of Rural Health
Professor John Zalcberg
Read More
Professor John Zalcberg OAM is the Monash Partners Cancer and Blood Diseases Theme Representative; Head, Cancer Research Program School of Public Health and Preventive Medicine at Monash University; and Tony Charlton Chair of Oncology, Alfred Health.
Professor Roger Daly
Read More
Professor Roger Daly is the Workforce and Education Director, MPCCC; and Head Department of Biochemistry and Molecular Biology, Monash University.
Ms Anna Kilgour
Read More
Ms Anna Kilgour is the Chief Operating Officer, MPCCC.
Ms Seleena Sherwell
Read More
Ms Seleena Sherwell is the Program Manager, Southern Melbourne Integrated Cancer Service .
You can find out more about Monash Partners Comprehensive Cancer Consortium work here or follow MPCCC on Twitter and LinkedIn
Monash Partners is proud to support the following projects within this Theme:
Using smart technology to more effectively and efficiently monitor the quality of cancer care
Professor John Zalcberg
Optimising lung cancer outcomes by using a clinical quality registry framed around value-based health care
Professor John Zalcberg
Innovative use of AI for antifungal stewardship in patients with blood cancer
Dr Michelle Ananda-Rajah
Real time surveillance of fungal infections to improve clinical care
Dr Michelle Ananda-Rajah
Improving access to new treatments for patients with Myeloma through a new clinical trials platform
Professor Andrew Spencer
Lung Cancer Clinical Quality Registry: a state-wide approach to monitoring and improving lung cancer care
Professor John Zalcberg
Establishing a Monash Partners national reference centre for molecular monitoring of residual disease in acute myeloid leukaemia
Associate Professor Andrew Wei
Exploratory analysis of circulating-free RNA as a non-invasive biomarker in multiple myeloma (MM) utilising the Myeloma and Related Diseases Registry (MRDR) and the Australasian Myeloma Research consortium (AMARC)
Professor Andrew Spencer
The PRECISE assay: Personalised medicine for cancer patients using next-generation sequencing
Dr Mark Waltham
From the Executive Director: The importance of plain language in health With Australia entering a new phase of the COVID pandemic, one where mandatory isolation has come to an end, many… more
‘Game-changing’ wound care directories launched Two open-access online resources launched today that will fill significant gaps in wound-related education and research in Australia. The Wounds… more
2022 MIME Seed Funding results Congratulations to the seven successful project teams in the 2022 MIME Seed Funding round. A fantastic array of opportunities… more